证券代码：002317 公告编号：2024-066 为进一步加强与投资者的互动交流，广东众生药业股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"坚定信心 理月活动投资者集体接待日"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 届时公司董事长、总裁陈永红先生，董事、副总裁、财务总监龙春华女士， 状况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 | --- | --- | --- | |------------------------------|--------------------------------------------------------------------|-------| | | 广东众生药业股份有限公司 | | | 关于参加广东辖区 | 2024 年投资者 | | | | 网上集体接待日活动的公告 | | | | | | | 记载、误导性陈述或重大遗漏。 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 | | 手共 ...

证券代码：002317 公告编号：2024-065 广东众生药业股份有限公司（以下简称"公司"）于 2023 年 10 月 30 日召开 第八届董事会第十一次会议和第八届监事会第十一次会议，审议通过《关于购买 理财产品的议案》，同意公司及子公司（公司合并报表范围内的子公司）在保障 日常生产经营以及项目建设资金需求，有效控制风险的前提下，由原使用不超过 人民币 30,000.00 万元调整至使用不超过人民币 70,000.00 万元的闲置自有资金 进行委托理财，期限相应调整为本次董事会审议通过之日起十二个月内，期限内 任一时点的交易金额不超过人民币 70,000.00 万元。在上述期限及额度内，资金 可滚动使用。本投资事项将在上述额度内，授权董事长具体实施相关事宜。 上述具体内容详见公司于 2023 年 10 月 31 日刊载在《证券时报》和巨潮资 讯网（www.cninfo.com.cn）的相关公告。 为提高闲置自有资金使用效率，在确保公司正常经营的前提下，公司于 2024 年 9 月 4 日使用闲置自有资金人民币 13,000.00 万元购买结构性存款保本型产品， 具体内容公告如下： 二、本次购买保本型产品 ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 6-month target price of 16.85 CNY per share [1][4][11]. Core Views - The company reported a revenue of 1.364 billion CNY for the first half of 2024, a decrease of 7.96% year-on-year, and a net profit of 87 million CNY, down 58.09% year-on-year [2][3]. - The early clinical data for the GLP-1R/GCCR dual-target peptide RAY1225 shows significant weight loss in obese subjects, indicating a differentiated advantage with bi-weekly dosing compared to the weekly dosing of competitors [2][3]. - The innovative drug, the flu medication Anladiwei, is expected to be approved for market release, with potential to contribute to revenue growth in the coming years [2][3]. Financial Summary - The company’s projected revenues for 2024, 2025, and 2026 are 3.007 billion CNY, 3.494 billion CNY, and 3.977 billion CNY, respectively, with corresponding net profits of 239 million CNY, 411 million CNY, and 532 million CNY [3][5][11]. - The earnings per share (EPS) are expected to be 0.28 CNY, 0.48 CNY, and 0.62 CNY for the years 2024, 2025, and 2026, respectively [3][5][11]. - The report anticipates a price-to-earnings (PE) ratio of 40.3, 23.4, and 18.1 for the years 2024, 2025, and 2026, respectively [5][11]. Revenue Breakdown - The company’s revenue from traditional Chinese medicine is projected to be 1.6 billion CNY in 2024, with a gross margin of 65% [7][8]. - The innovative drug segment is expected to generate revenues of 1.4 billion CNY in 2024, with a gross margin of 95% [7][8]. - The chemical generic drug business is projected to have revenues of 9.8 billion CNY in 2024, maintaining a gross margin of 50% [7][8].

关于控股子公司一类创新药 RAY1225 注射液 新增适应症临床试验注册申请获得受理的公告 申请事项：境内生产药品注册临床试验 受理号：CXHL2400894 证券代码：002317 公告编号：2024-064 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）自主研发的一类创新多肽药 物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝炎（MASH）"的药物 临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。具体情况 如下： 一、《受理通知书》主要内容 1、产品名称：RAY1225 注射液 RAY1225 能选择性结合并激活 GIP 和 GLP-1 受体，以葡萄糖依赖的方式促 进胰岛素分泌和抑制胰高血糖素从而控制血糖，同时抑制胃排空，抑制食欲，降 低体重，降低外周胰岛素抵抗，改善肝脏脂肪变性和气球样变等。目前，全球首 款 GLP-1/GIP 双重受体激动剂替尔泊肽（Tirzepatide）已在国内获批上市 ...

证券代码：002317 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 总计 | - | - | - | | | | | | | | | | - | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往 来方名 | 往来方与上 市公司的关 | 上市公司核 算的会计科 | 2024 初往来资 | 年期 | 2024 年半度 | 2024 | 年半度 | 2024 年半 度偿还累计 | 2024 | 年半 度期末往来 | | 往来性质 | | | | | | | | 往来累计发 | 往来资金的 | | | | | 往来形 | （经营性往 | | | | | | | | 生金额（不 | 利息（如 | | | | | 成原因 | 来、非经营 | | | 称 | 联关系 | 目 | 金余额 | | | | | 发生金额 | | 资金余额 | | | | | | | | | | 含利息） | 有） | | | | | | 性往来） | | 控股股东、实 ...

证券代码：002317 公告编号：2024-059 广东众生药业股份有限公司 表决结果：9 票同意，0 票反对，0 票弃权。 备 注 ： 具 体 内 容 详 见 信 息 披 露 媒 体 ：《 证 券 时 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）。 二、审议通过了《2024 年半年度募集资金存放与使用情况的专项报告》。 表决结果：9 票同意，0 票反对，0 票弃权。 备注：《2024 年半年度募集资金存放与使用情况的专项报告》详见信息披 露媒体：《证券时报》和巨潮资讯网（www.cninfo.com.cn）。 三、审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。 为提高募集资金使用效率，增加资金收益，公司在确保不影响募集资金投资 计划正常进行的情况下，拟使用不超过人民币 28,000.00 万元的闲置募集资金进 行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。 第八届董事会第十五会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第十五次会 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 1,364,366,722.80, a decrease of 7.96% compared to the same period last year, which was CNY 1,482,289,475.29[11]. - The net profit attributable to shareholders of the listed company was CNY 87,409,781.47, representing a decline of 58.09% from CNY 208,550,306.83 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was CNY 173,681,640.27, down 24.28% from CNY 229,386,194.95 year-on-year[11]. - The basic earnings per share decreased by 61.54% to CNY 0.10 from CNY 0.26 in the same period last year[11]. - The total profit for the first half of 2024 was CNY 99,607,653.39, a decrease of 57.40% from CNY 233,352,361.75 in the first half of 2023[166]. - The company reported a net profit for the first half of 2024 of CNY 78,834,290.52, down 62.96% from CNY 212,248,753.83 in the first half of 2023[166]. - The company reported a total comprehensive income for the first half of 2024 of approximately CNY 78.4 million, a decrease of 36.3% compared to CNY 123.03 million in the same period of 2023[169]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,790,409,914.42, a decrease of 10.34% from CNY 6,458,522,399.09 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were CNY 4,281,827,959.23, down 1.71% from CNY 4,356,304,632.27 at the end of the previous year[11]. - Total liabilities decreased from CNY 1,932,845,785.58 to CNY 1,347,013,455.56, a reduction of approximately 30.3%[160]. - The company's cash and cash equivalents decreased from CNY 1,252,043,320.29 to CNY 971,641,672.77, representing a decline of approximately 22.4%[158]. - Accounts receivable increased from CNY 480,537,798.48 to CNY 563,565,324.50, reflecting a growth of about 17.3%[158]. - The company's total equity at the end of the reporting period was 4,443,396,458.86 CNY, demonstrating growth in asset base[176]. Cash Flow - The net cash flow from operating activities was CNY 212,633,164.11, an increase of 235.57% compared to CNY 63,364,378.70 in the previous year[11]. - Cash inflow from operating activities was CNY 1.28 billion, a decrease of 5.2% from CNY 1.35 billion in the first half of 2023[170]. - Cash inflow from investment activities reached CNY 922.47 million, up 125.5% from CNY 409.70 million in the first half of 2023[171]. - The net cash flow from financing activities was negative at CNY -890.44 million, contrasting with a positive CNY 552.33 million in the same period last year[171]. Research and Development - The company emphasizes innovation in drug development and aims to become a leading pharmaceutical health industry group in China[18]. - The company has established a well-structured R&D ecosystem, emphasizing independent research complemented by collaborative efforts to meet unmet clinical needs, which enhances its product pipeline[25]. - The company’s R&D investment has exceeded 12% of its annual revenue in 2023, continuing a trend of over 8% in previous years[33]. - The company has 7 innovative drug projects in clinical trials, with 1 drug approved for market (Lai Ruitewei tablets) and 1 new drug application accepted (Angladi tablets)[29]. Market Position and Strategy - The company is focusing on a mid-term strategic positioning as a "Chinese medicine-based, innovation-driven, specialty pharmaceutical health enterprise," adapting to changes in the pharmaceutical industry[26]. - The company is actively pursuing market expansion strategies, including optimizing its product pipeline and enhancing academic promotion efforts to drive sustainable growth[25]. - The company has established strong partnerships with CROs, research institutions, and medical organizations to foster deep collaboration in research and development[25]. - The company is committed to rapid commercialization of innovative drug projects and exploring new drug development opportunities in traditional Chinese medicine[18]. Environmental and Compliance - The company adheres to multiple environmental protection laws, including the Environmental Protection Law of the People's Republic of China and the Air Pollution Prevention and Control Law[86]. - The company has implemented strict environmental impact assessments for construction projects, ensuring compliance with regulations[86]. - The company has successfully passed all environmental impact evaluations and completed acceptance work as per regulations[86]. - The company has implemented a self-monitoring plan for environmental emissions, with quarterly monitoring for wastewater and annual monitoring for waste gas[94]. Shareholder and Governance - The company emphasizes the protection of shareholder and creditor rights, adhering to relevant laws and regulations to enhance corporate governance and operational standards[97]. - The company has made a commitment not to reduce its shareholding for six months from August 24, 2023, to February 24, 2024, to support market stability[99]. - The company held its annual general meeting on May 14, 2024, with an investor participation rate of 28.89%[78]. - The company has not reported any significant events affecting its ability to continue as a going concern[187]. Risks and Challenges - The company has acknowledged potential risks including industry risks, rising costs, R&D risks, and uncertainties in subsidiary performance[2]. - The company is facing industry risks due to price declines in drug procurement and potential market access difficulties, which could adversely affect revenue[75]. - Rising costs of raw materials, labor, and environmental compliance are putting pressure on the company's overall operating costs[75]. - The company plans to strengthen management and training for its subsidiaries to stabilize and improve their performance[75].

证券代码：002317 公告编号：2024-063 广东众生药业股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 了第八届董事会第十五次会议及第八届监事会第十五次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资计划正常进行的情况下，使用不超过人民币 28,000.00 万元的闲置募集资金 进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。 现金管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限 内资金可滚动使用，但在任一时点的实际投资金额不超过人民币 28,000.00 万元， 本次使用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体 实施相关事宜。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等相关规定，本事项属于公司董事会审批权限范围，无需提交公司股东大会审议。 现将具体情况公告如下： 一、公司募集资金基本情况 经中国证券 ...

证券代码：002317 公告编号：2024-060 广东众生药业股份有限公司 第八届监事会第十五次会议决议公告 经审核，监事会认为董事会编制和审议公司 2024 年半年度报告的程序符合 法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 二、审议通过了《2024 年半年度募集资金存放与使用情况的专项报告》。 监事会认为，该报告真实、客观地反映了公司募集资金存放与使用的情况。 监事会对《2024 年半年度募集资金存放与使用情况的专项报告》无异议。 表决结果：3 票同意，0 票反对，0 票弃权。 三、审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。 经审核，监事会认为公司使用部分暂时闲置募集资金进行现金管理履行了必 要的审批程序，内容及程序符合募集资金使用的相关规定，有利于提高募集资金 第 1 页 共 2 页 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第十五次会 议 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意广东众生药业股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2023〕891 号）同意，广东众生药业股份有 限公司（以下简称"公司"）向 12 名特定对象发行人民币普通股（A 股）38,969,401 股，发行价格为 15.36 元/股，实际募集资金总额为 598,569,999.36 元，扣除各项 发行费用 8,373,028.97 元（不含税）后，募集资金净额为 590,196,970.39 元，本 次发行募集资金已于 2023 年 6 月 15 日全部汇入公司指定存储账户，并由众华会 计师事务所（特殊普通合伙）进行了验证，于 2023 年 6 月 16 日出具《验资报 告》（众会字（2023）第 07869 号）。 （二）以前年度已使用金额、本报告期使用金额及当前余额 截至 2024 年 6 月 30 日，公司累计使用募集资金人民币 304,398,243.55 元， 其中，以前年度累计投入 294,030 ...